Reduced gastrointestinal motility throughout the digestive tract prolongs the period during which nutrient sensors in the gut wall send satiety signals
Non-surgical interventions can be beneficial
Do not decide on your own when to hold or restart a prescription
When to seek medical advice: If you experience muscle pain, weakness, or dark urine whilst taking statins (potential signs of myopathy) If severe, persistent abdominal pain occurs whilst on GLP-1 therapy (potential pancreatitis) If cholesterol reduction is not achieved despite treatment adherence Before stopping or changing any prescribed medication If you develop new symptoms or side effects from any therapy Patients should discuss their individual cardiovascular risk profile and treatment options with their GP or specialist
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
For people who do not mind a once-weekly injection , the frequency advantage goes to GLP-1 medications